Objective-The SAVE study showed that captopril improves mortality in patients with left ventricular dysfunction after myocardial infarction and that this benefit occurred even in patients with no clinically overt heart failure. On the basis of this, it seems important to identify correctly which patients have left ventricular dysfunction after a myocardial infarc- 
Abstract
Objective-The SAVE study showed that captopril improves mortality in patients with left ventricular dysfunction after myocardial infarction and that this benefit occurred even in patients with no clinically overt heart failure. On the basis of this, it seems important to identify correctly which patients have left ventricular dysfunction after a myocardial infarction. The objective was to compare various methods of identifying patients with left ventricular dysfunction (left ventricular ejection fraction, LVEF, <40%) after acute myocardial infarction. The methods compared were echocardiography (quantitative and qualitative visual assessment), clinical evaluation (subjective assessment and three clinical score methods), and measurement of plasma concentrations of cardiac natriuretic peptide hormones (atrial and brain natriuretic peptides, ANP and BNP). Design-Cross sectional study of left ventricular function in patients two to eight days after acute myocardial infarction. Setting 15 The sensitivity of this technique, however, depends on both the operator and the nature of the measurement. More recently, there has been interest in the measurement of plasma neurohormones as a measure of left ventricular dysfunction.16 17 The cardiac natriuretic peptide hormones, atrial natriuretic peptide (ANP) and brain natriuretic peptide (BNP), are both high after an acute myocardial infarction18 19 and in chronic heart failure.20 The patients who underwent radionuclide ventriculography within three days of their clinical, echocardiographic, and neurohormonal assessment. These patients were identical in all clinical aspects to those who did not undergo radionuclide ventriculography. The radionuclide ventriculography LVEF ranged from 10% to 68% with a median value of 45%. These radionuclide ventriculography data serve mainly as reassurance that our echocardiographically calculated LVEFs were accurate as there was a reasonably good relation between the LVEFs calculated by both methods in those patients (n = 23) who underwent both procedures. The echocardiographic calculations systematically underestimated the LVEF compared with radionuclide ventriculography by 6-2% (6 9%) (mean (SD)) as has been reported before.'4 Part of this difference in our study may be the three day gap between the two measurements.
DIFFERENT LVEF CRITERIA Table 3 shows how various methods perform if the cut off point for ACE inhibitor treatment is moved from LVEF < 40% to either LVEF < 35% or LVEF < 45%. This information may be useful because the LVEF 40% cut off point in the SAVE study was arbitary. Physicians and cardiologists would probably prefer to overtreat these patients with ACE inhibitors rather than undertreat them so that the data for LVEF < 45% are of more interest than the data for LVEF < 35%. At the cut off point of an LVEF < 45%, the overall results are similar to those of an LVEF < 40%-that is, qualitative assessment of the echocardiogram-and plasma BNP are the most sensitive methods available, with sensitivities of 71% and 81%. In the clinical assessment of left ventricular dysfunction, both clinical impression and clinical scores were studied. The Killip score, which is based entirely on physical findings alone, clearly is of limited value in this group of patients. The Peel index was originally designed as a prognostic indicator in patients with acute myocardial infarction rather than as an indicator of left ventricular dysfunction but as it assesses the haemodynamic derangement produced, we thought that it might also reflect left ventricular dysfunction after an acute myocardial infarction. The Peel index itself does not include site of infarction, the maximum rise in creatine kinase, or radiological findings, which may well contribute to left ventricular function after an acute myocardial infarction."-'5 Thrombolysis is a new entity since the original Peel index was devised and this is clearly another main influence on left ventricular dysfunction. Therefore we included thrombolysis along with the other variables into our modified Peel index. By incorporating these variables, we were able to improve its level of sensitivity. None the less, our data showed that clinical assessment or a clinical scoring system are still unreliable and likely to overlook up to half of the patients who would benefit from ACE inhibitor treatment. Indeed, our findings support previous studies showing that clinical evaluation is inadequate in detecting left ventricular dysfunction after an acute myocardial infarction.33'436 The reason for this may be that patients with depressed left ventricular ejection fractions initially have an increase in end systolic rather than end diastolic volume and it is thought that only when both volumes are increased does haemodynamic decompensation become clinically apparent.3437
The cardiac hormone ANP is synthesised and released mainly from the atria in response to atrial distension, and produces natriuresis, vasodilation, and diuresis in humans. Pathological increases are found both after an acute myocardial infarction and in patients with chronic heart failure, but reports of its value as a marker of left ventricular function have been conflicting.2138 In patients with an acute myocardial infarction, ANP tends to rise early and peak two to four days later.2239 Some increase is seen even in the absence of any left ventricular dysfunction or increased left ventricular pressure.39" Indeed, a basal release of ANP may occur as a general response to stress or even as a leak from infarcting or ischaemic tissue. This may be why plasma ANP was such a poor indicator of left ventricular dysfunction after a myocardial infarction.
Although originally isolated from the porcine brain as a putative neurotransmitter, BNP is mainly a cardiac hormone like ANP.20 23 41 By striking contrast with ANP, BNP is predominantly synthesised and secreted in the cardiac ventricle and it may therefore be a more sensitive index of ventricular function.42 Indeed, Mukoyama et al have reported increased plasma concentrations of BNP that correlated strongly with the severity of disease in patients with chronic heart failure.20 Two previous studies have examined BNP secretion after acute myocardial infarction. In a small group of 13 patients, Mukoyama et al found that BNP but not ANP correlated inversely with cardiac index. 19 More recently, we found that BNP correlated better than ANP with LVEF although that study was performed in a highly selected group of patients with anterior, Q wave first acute myocardial infarction.43 In our present study, BNP secretion was evaluated in a larger and totally heterogenous group of patients and we still found that BNP was a better predictor of a reduced LVEF < 40% than ANP. There were, however, more false positives than in our previous study-that is, in this study there was a subgroup of patients with normal LVEFs but with unexplained high BNP concentrations. The reasons for this difference are probably multiple including the heterogenous nature of these patients. Also According to this study, such an approach would halve the number of echocardiograms needed for this group of patients.
